Agenus | AGEN - Debt


Agenus reported $35.54M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Agenus USD 35.54M 2.34M Mar/2025
Amgen USD 54.6B 17M Dec/2025
AstraZeneca USD 33.92B 4.3B Mar/2026
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Celldex Therapeutics USD 2.34M 285K Dec/2025
CSL USD 11.96B 219M Dec/2024
Eli Lilly USD 42.5B 3.6M Dec/2025
Gilead Sciences USD 24.94B 5M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Glaxosmithkline GBP 17.75B 396M Sep/2025
Incyte USD 39.43M 982K Mar/2026
Intrexon USD 0 13.82M Jun/2024
J&J USD 47.93B 2.14B Dec/2025
Jiangsu Hengrui CNY 74.23M 17.2M Dec/2025
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
MacroGenics USD 37.01M 238K Sep/2025
Merck EUR 11.95B 152M Dec/2025
Merck USD 49.34B 7.97B Dec/2025
Northwest Biotherapeutics USD 32.94M 6.93M Sep/2023
Novartis USD 47B 11.62B Mar/2026
Novavax USD 233.31M 4.23M Sep/2024
Pfizer USD 63.73B 231M Mar/2026
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Rigel Pharmaceuticals USD 59.69M 90K Jun/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 39.65M 799K Dec/2025